Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study
Panaccione R, Long M, Ran Z, Atreya R, Nakase H, Zhou W, Yao X, Ilo D, D'Haens G (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: LIPPINCOTT WILLIAMS & WILKINS
City/Town: PHILADELPHIA
Pages Range: S574-S575
Conference Proceedings Title: AMERICAN JOURNAL OF GASTROENTEROLOGY
DOI: 10.14309/01.ajg.0000859860.18839.f9
Authors with CRIS profile
Raja Atreya
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)
Involved external institutions
AbbVie Deutschland GmbH & Co. KG
Germany (DE)
University of Amsterdam
Netherlands (NL)
Sapporo Medical University / 札幌医科大学
Japan (JP)
University of North Carolina at Chapel Hill
United States (USA) (US)
Shanghai Jiao Tong University / 上海交通大学
China (CN)
University of Calgary
Canada (CA)
Germany (DE)
University of Amsterdam
Netherlands (NL)
Sapporo Medical University / 札幌医科大学
Japan (JP)
University of North Carolina at Chapel Hill
United States (USA) (US)
Shanghai Jiao Tong University / 上海交通大学
China (CN)
University of Calgary
Canada (CA)
How to cite
APA:
Panaccione, R., Long, M., Ran, Z., Atreya, R., Nakase, H., Zhou, W.,... D'Haens, G. (2022). Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study. In AMERICAN JOURNAL OF GASTROENTEROLOGY (pp. S574-S575). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
MLA:
Panaccione, Remo, et al. "Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study." Proceedings of the AMERICAN JOURNAL OF GASTROENTEROLOGY PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2022. S574-S575.
BibTeX: Download